Please ensure Javascript is enabled for purposes of website accessibility

Early Results Dampen Outlook for Experimental COVID-19 Treatment

By Cory Renauer - Mar 14, 2020 at 12:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unofficial early data from the first few COVID-19 patients given an experimental treatment are not what we hoped for.

A potential coronavirus treatment called remdesivir entered a clinical trial in February after positive anecdotal reports from the first patients treated with the experimental antiviral. The company that owns remdesivir, Gilead Sciences (GILD 0.80%), hasn't released any official data from the ongoing study but we recently received an unofficial preview that's less than encouraging.

Preliminary problems

A paper describing the first 12 patients with COVID-19 in the U.S. started circulating ahead of an official peer review, and it doesn't look great for remdesivir. While the paper didn't have anything negative to say about efficacy, there were some unsettling safety signals.

Coronavirus blood vial

Image source: Getty Images.

All three patients treated with remdesivir recovered, but they also reported significant gastrointestinal symptoms. Investigators also noticed elevated liver enzyme levels in their blood samples.

Given the lack of available virus-attacking treatments for COVID-19, some gastrointestinal discomfort isn't such a big deal, but elevated liver enzymes could nail remdesivir's coffin shut. 

Too early to judge

While all three experienced gastrointestinal issues, one was complaining of diarrhea before receiving remdesivir. Nothing tanks an experimental new drug faster than elevated liver enzymes, but concentrations among some patients that weren't treated with remdesivir peaked higher than those that were.

Before dismissing Gilead Sciences' experimental antiviral, it's important to understand these are not results from a clinical trial designed to measure safety or efficacy. Among the 12 patients observed, only the three most seriously affected were given remdesivir. That's the exact opposite of the randomization taking place in the ongoing clinical trial.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.08 (0.80%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.